Ferrous Sulfate Remains First-Line for Iron Deficiency Anemia
Start with ferrous sulfate (or another ferrous salt) at 60-110 mg elemental iron once daily—it is effective, inexpensive, and supported by the strongest guideline evidence, despite gastrointestinal side effects. 1 Sucrosomial iron may offer better tolerability with comparable efficacy, but the evidence is limited and it costs significantly more, making it a reasonable second-line option when ferrous sulfate is not tolerated.
Initial Treatment Approach
The 2025 Lancet Haematology guidelines provide a strong recommendation for oral iron salts as first-line therapy for iron deficiency anemia in adults without malabsorptive conditions 1. The expert panel explicitly states there is insufficient evidence to support one oral iron formulation over another, and recommends starting with an iron salt (ferrous sulfate, gluconate, or fumarate) containing 60-110 mg elemental iron daily 1. Standard ferrous sulfate tablets contain 324 mg ferrous sulfate, equivalent to 65 mg elemental iron 2.
Dosing Strategy
- Once daily dosing only: Never dose oral iron more than once daily—hepcidin elevation persists up to 48 hours after a dose, blocking further absorption while increasing side effects 1
- Alternate-day dosing: If daily dosing causes intolerable GI side effects, switch to alternate-day dosing, which maintains similar efficacy with reduced side effects 1
- Timing: Take with water at bedtime to minimize dietary interference from dairy, phytates, coffee, tea, and calcium 1
Sucrosomial Iron: When to Consider
Sucrosomial iron is a newer formulation of ferric pyrophosphate encapsulated in a phospholipid matrix. The limited available evidence suggests:
Efficacy
A 2024 retrospective study (n=260) found sucrosomial iron produced significantly higher hemoglobin improvement (12.20 g/dL) compared to ferrous fumarate (11.72 g/dL) and ferrous ascorbate (11.86 g/dL) at 3 months 3. However, a 2025 prospective IBD study showed no difference in efficacy between sucrosomial iron and ferric hydroxide-polymaltose complex, with only 22% of patients achieving target iron parameters at 12 weeks 4.
Tolerability
The key advantage appears to be tolerability:
- In the 2025 IBD study, only 8.7% of sucrosomial iron patients experienced side effects versus 30.3% with ferric hydroxide-polymaltose 4
- A 2019 IBD study reported only 30% of patients had gastrointestinal events with sucrosomial iron, with none considered certainly related to treatment 5
- By contrast, ferrous sulfate causes constipation in 12%, diarrhea in 8%, and nausea in 11% of patients 6
Critical Decision Points
When Ferrous Sulfate Fails or Is Inappropriate
Switch to intravenous iron (not sucrosomial iron) if 1:
- No hemoglobin rise after 4-12 weeks of adequate oral therapy
- Intolerable side effects despite alternate-day dosing
- Malabsorptive conditions (IBD, celiac disease, post-bariatric surgery)
- Chronic kidney disease
- Need for rapid correction
The 2025 guidelines give a moderate strength recommendation for IV iron in these scenarios, noting superior hemoglobin increases (mean difference 4.65-5.7 g/dL vs placebo) with low risk of serious adverse events 1.
When to Consider Sucrosomial Iron
Sucrosomial iron is a reasonable option when:
- Patient cannot tolerate ferrous sulfate even with alternate-day dosing
- Cost is not prohibitive (it is significantly more expensive than ferrous salts)
- Patient has mild-to-moderate IDA without urgent need for correction
- Inflammatory bowel disease with concerns about GI tolerability 5
Important Caveats
Do not use enteric-coated or slow-release formulations—these deliver iron beyond the proximal small intestine where absorption is optimal, reducing effectiveness despite marketing claims of better tolerance 1. This applies to enteric-coated ferrous sulfate products 2.
The 2025 AGA guidelines note that "there is no substantial evidence that any one [oral iron] product is better than another—either in effectiveness or tolerance" 6. The toxicity and efficacy depend more on elemental iron dose than formulation type 1.
Practical Algorithm
- Start: Ferrous sulfate 324 mg (65 mg elemental iron) once daily at bedtime with water
- If GI intolerance: Switch to alternate-day dosing
- If still intolerant: Consider sucrosomial iron 30 mg daily (if cost acceptable) OR proceed to IV iron
- If no response at 4-12 weeks: Switch to IV iron (ferric carboxymaltose or iron sucrose)
- Reassess: Check hemoglobin and ferritin at 4 weeks, expect 1 g/dL hemoglobin rise in 2 weeks if adherent 6
The evidence does not support routine use of sucrosomial iron as first-line therapy over ferrous sulfate, but it represents a valid intermediate option before escalating to intravenous iron in patients with tolerability issues.